Financings

4D Molecular Therapeutics Inc. closed a $90 million series B financing round.

Allogene Therapeutics Inc. completed a $120 million private financing of convertible notes.

Evox Therapeutics Ltd. closed an oversubscribed £35.5 million (US$46.1 million) series B round.

Fulcrum Therapeutics Inc. generated $80 million from a series B round.

Harbour Biomed Therapeutics Ltd. completed a series B financing of $85 million.

Kalvista Pharmaceuticals Inc. priced its underwritten public offering with gross proceeds expected to be approximately $68 million.

Oberland Capital closed its second royalty and credit opportunities fund, Oberland Capital Healthcare II LP, at its hard cap of $800 million in capital commitments.

Oncosec Medical Inc. said it secured a $15 million investment from Alpha Holdings Inc.

Phasebio Pharmaceuticals Inc. said it completed a $34 million series D financing round.

Principia Biopharma Inc. has established terms for its proposed $75 million IPO and is planning to sell 4.68 million shares priced between $15 and $17 per share.

Retrophin Inc. priced its offering of $240 million aggregate principal amount of 2.50 percent convertible senior notes due 2025.

Twentyeight-Seven Therapeutics Inc. generated $65 million from a series A round.

Westlake Village Biopartners, a new life sciences venture firm, said it launched its first fund with $320 million of committed capital.

Zai Lab Ltd. priced its underwritten public offering of $150 million of American Depositary shares representing ordinary shares of the company.

Deals

Atara Biotherapeutics Inc. entered a deal with Moffitt Cancer Center to develop multitargeted CAR T immunotherapies for patients with acute myeloid leukemia and B-cell malignancies.

Aurobindo Pharma USA Inc. has agreed to pay Novartis AG's generics division, Sandoz Inc., up to $1 billion for a basket of dermatology and generic oral medicines that the Swiss drugmaker is divesting.

Beigene Ltd. and Springworks Therapeutics LLC are collaborating to evaluate the safety, tolerability and preliminary efficacy of combining Beigene's RAF dimer inhibitor, lifirafenib (BGB-283) and Springworks' MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

Biotime Inc. closed its transaction with Juvenescence Ltd., selling 14.4 million shares of Agex Therapeutics Inc., a biotech company focused on the development of therapeutics for age-related degenerative disease, for $43.2 million.

GNS Healthcare has partnered with Amgen Inc. and the Alliance for Clinical Trials in Oncology to apply causal artificial intelligence and simulation to combined trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer.

JW Pharmaceutical Corp. out-licensed its atopic dermatitis candidate, JW-1601, to Leo Pharma A/S.

Ossianix Inc. entered a research collaboration and option agreement with Novo Nordisk A/S to deliver therapeutic molecules in diabetes and other metabolic diseases across the blood-brain barrier.

Otsuka Pharmaceutical Co. Ltd. completed the acquisition of Visterra Inc. for about $430 million in an all-cash transaction.

Precision Biosciences Inc. expanded an ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania to pursue research and development of gene editing therapies.

Reata Pharmaceuticals Inc. received a $30 million milestone payment from its licensee, Kyowa Hakko Kirin Co. Ltd., following the initiation of a phase III trial to assess the efficacy and safety of bardoxolone methyl for the treatment of diabetic kidney disease in Japan.

Shire plc completed the sale of its oncology franchise to Servier S.A.S. for $2.4 billion.

United Therapeutics Corp. and Mannkind Corp. inked an exclusive global licensing and collaboration agreement to develop and commercialize a dry powder formulation of treprostinil to treat pulmonary arterial hypertension.

. . . And more

By simultaneously targeting two opioid receptor subtypes, researchers from Wake Forest School of Medicine and Astraea Therapeutics Inc. have developed a compound that, in nonhuman primates, was an effective analgesic that not only lacked the rewarding effects of currently used opioid analgesic, but blocked those effects, making it a potential treatment for both pain and opioid addiction.

The first China-discovered and developed treatment for colorectal cancer, fruquintinib, won approval from the National Medical Products Administration of China, marking Hutchison China Meditech Ltd.'s first approval for an innovative medicine. The National Health Service (NHS) has agreed to reimburse treatment with Novartis AG's Kymriah CAR T immunotherapy, little more than a week after the product received formal approval from the European Commission.

Thrombogenics NV said its shareholders approved its name change to Oxurion NV. The company's ticker will change from THR to OXUR.

No Comments